Corporate Presentation

On January 5, 2018 Affimed N.V. presented January 2018 Corporate Presentation (Presentation, Affimed, JAN 5, 2018, View Source [SID1234522927]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, January 31, 2018

On January 5, 2018 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that it will release its financial results for the 2017 fourth quarter and full year before the market opens on Wednesday, January 31, 2018, and will hold a conference call on the same day at 8:30 a.m. EDT (Press release, Thermo Fisher Scientific, JAN 5, 2018, View Source [SID1234522926]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the call, the company will discuss its fourth quarter financial performance, as well as future expectations. To listen, call (844) 579-6824 within the U.S. or (763) 488-9145 outside the U.S. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can be found in that section of our website under "Financial Results." A replay of the call will be available under "Webcasts and Presentations" through Thursday, February 1, 2018.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Radius Health to Present at the 36th Annual J.P. Morgan Healthcare Conference

On January 5, 2018 Radius Health, Inc. (Nasdaq:RDUS), reported that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 11:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, California (Press release, Radius, JAN 5, 2018, View Source [SID1234522925]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors section of Radius’ website at View Source A replay of the webcast will be archived on Radius’ website for 30 days following the presentation.

Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement

On January 5, 2018 Eli Lilly and Company (NYSE: LLY) reported that it will announce its fourth-quarter and full-year 2017 financial results on Wednesday, January 31, 2018 (Press release, Eli Lilly, JAN 5, 2018, View Source [SID1234522923]). Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at View Source A replay will also be available on the website following the conference call.

Nantworks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Francisco, CA

On January 5, 2018 NantWorks, the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) reported that Dr. Patrick Soon-Shiong (Chairman, CEO, and Founder) will present the current status of these companies and the overall ecosystem of NantWorks (Press release, NantKwest, JAN 5, 2018, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2325231 [SID1234522931]). Specific details will be presented regarding the current status of GPS CancerTM, including FDA filings and seminal patents issued covering tumor-normal analysis of DNA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, details will be presented regarding the record 25 letters of authorization covering 12 novel biological molecules tested across 20 tumor types within the NantWorks ecosystem of companies, of which 15 letters of authorization were received in 2017 for natural killer cells in combination with adenovirus, yeast, super agonist IL-15 and checkpoint inhibitors. The preliminary results of the first in human and safety studies of the NANT Cancer Vaccine will be released.

Presentation Time:

Time: January 9, 2018 at 5:00pm Pacific Time.
Location: 36th Annual J.P. Morgan Healthcare Conference – Elizabethan A/B Breakout: Sussex Room
Both the presentation and question and answer session that follows at 5:00pm will be webcast live at the below links and available for replay at both NantHealth and NantKwest.

NantWorks Presents at the 36th Annual J.P. Morgan Healthcare Conference
NantWorksQ & A Session at the 36th Annual J.P. Morgan Healthcare Conference